Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07159841 · ClinicalTrials.gov registry record · Phase 2

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

A Phase 2 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia, sponsored by Crinetics Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
153
Enrollment target
18
Study locations

NCT07159841 is a Phase 2 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia that is actively recruiting participants, run by Crinetics Pharmaceuticals. The registered enrollment target is 153 participants, above the 83-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (84% higher). The trial reports 18 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07159841, a Phase 2 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia, is actively recruiting participants, sponsored by Crinetics Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
153 participants
Enrollment target
18
Study locations

Study Summary

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).

Conditions Studied

Congenital Adrenal Hyperplasia Classic Congenital Adrenal Hyperplasia

Interventions

  • DRUG Placebo
  • DRUG Atumelnant

Study Locations (18)

Other

  • Hospital Italiano de Buenos Aires - Buenos Aires
  • Instituto Médico Especializado (IME) - Buenos Aires
  • Hopital Kremlin-Bicétre - APHP Paris Saclay - Le Kremlin-Bicêtre
  • Hopital Robert Debre - Paris

Michigan

  • University of Michigan - Ann Arbor

Minnesota

  • University of Minnesota - Minneapolis

New Jersey

  • Rutgers Robert Wood Johnson Medical School - New Brunswick

Texas

  • Cook Children's Health Care System - Fort Worth

Virginia

  • University of Virginia Health System - Charlottesville

New South Wales

  • Institute of Endocrinology of Diabetes, The Children's Hospital at Westmead - Westmead

Queensland

  • Queensland Children's Hospital - South Brisbane

Trial Details

FieldValue
Enrollment Target 153 participants
Start Date 2026-01-22
Est. Completion 2030-03
Phase Phase 2

Sponsor

Crinetics Pharmaceuticals

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07159841

The ClinicalTrials.gov registry entry for NCT07159841 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 83-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (84% higher). The listed sponsor is Crinetics Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Congenital Adrenal Hyperplasia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07159841 reports 18 study locations spanning 15 distinct geographic areas - top geographies include Other, Michigan, Minnesota.

Frequently Asked Questions

What is clinical trial NCT07159841 about?

NCT07159841 is a clinical study titled "A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)". The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).

What is the current status of trial NCT07159841?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2026-01-22. Estimated completion is 2030-03.

What conditions does trial NCT07159841 study?

This clinical trial studies the following conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia.

What interventions are being tested in trial NCT07159841?

The interventions under investigation include: Placebo (DRUG), Atumelnant (DRUG).

Who is sponsoring clinical trial NCT07159841?

This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07159841 being conducted?

This trial has 18 study locations across Michigan, Minnesota, New Jersey, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Congenital Adrenal Hyperplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Congenital Adrenal Hyperplasia

All registered trials for this condition

Classic Congenital Adrenal Hyperplasia

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.